Neko Health is a health-tech startup specializing in advanced body-scanning technology for comprehensive, non-invasive, and cost-effective health monitoring. Unlike traditional diagnostics, which are often expensive and reactive, Neko’s approach focuses on early detection and preventive care. Its technology provides individuals with detailed health insights in a convenient and accessible manner, helping to identify potential issues before they escalate. By prioritizing proactive healthcare, Neko aims to reduce the burden on medical systems while improving overall patient outcomes.
Neko Health has raised $260 million in a Series B funding round that values Neko at $1.8 billion. The new round was led by Lightspeed Venture Partners, a new investor in the company, with General Catalyst, O.G. Venture Partners, Rosello, Lakestar, and Atomico participating. Neko plans to use the capital to expand into new markets such as the U.S., advance its diagnostics capabilities potentially through acquisitions, and open more clinics to meet growing demand.
Neko Health, Stockholm, Stockholms Lan, Sweden, was founded in 2018 by Daniel Ek and Hjalmar Nilsonne. The company currently operates in Sweden and the UK, with plans to expand further into Europe and enter the U.S. market. With its innovative approach to preventive healthcare and strong investor backing, Neko Health is poised to redefine the future of global health monitoring.
Share this post